You are here

  • Home
  • Archive
  • Volume 9, Issue 5
  • In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

Article metrics

Article menu
XML
Oncolytic and local immunotherapy
Original research
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models

 

Online download statistics by month:

Online download statistics by month: May 2021 to July 2025

AbstractFullPdf
May 202126426485
Jun 2021687696228
Jul 2021526526121
Aug 2021301301110
Sep 202113213263
Oct 202117717788
Nov 202119018978
Dec 202112612745
Jan 202211712157
Feb 202210811375
Mar 202212413163
Apr 202211912363
May 202211612351
Jun 202212713774
Jul 202211412271
Aug 202212813866
Sep 202213614378
Oct 202213914654
Nov 202215215264
Dec 2022969757
Jan 2023818238
Feb 202311511553
Mar 2023919269
Apr 2023666751
May 2023555538
Jun 2023838341
Jul 2023808049
Aug 2023636444
Sep 2023787937
Oct 2023767633
Nov 2023828231
Dec 2023757535
Jan 2024747559
Feb 2024666938
Mar 2024929457
Apr 2024868652
May 2024727241
Jun 2024777742
Jul 2024878841
Aug 2024696788
Sep 2024565626
Oct 2024717153
Nov 2024646638
Dec 2024919249
Jan 2025768049
Feb 2025838457
Mar 2025909064
Apr 202511911972
May 2025737452
Jun 2025868649
Jul 2025110
Total625763553037